Novartis AG

Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer (2025) Lüftner D, Banys-Paluchowski M, Hartkopf AD, Hörner M, Janni W, Langanke D, Müller V, et al. Journal article Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN) (2025) Schmitz-Dräger BJ, Bismarck E, Ebert T, Starlinger R, Dienes K, Ottillinger B, Goebell P, et al. Journal article Evaluating the Accuracy and Reliability of Real-World Digital Mobility Outcomes in Older Adults After Hip Fracture: Cross-Sectional Observational Study (2025) Berge MA, Paraschiv-Ionescu A, Kirk C, Küderle A, Micó-Amigo E, Becker C, Cereatti A, et al. Journal article Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer (2024) Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, et al. Journal article Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device (2024) Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, et al. Journal article Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158) (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article, Erratum Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article Toward designing human intervention studies to prevent osteoarthritis after knee injury: A report from an interdisciplinary OARSI 2023 workshop (2024) Whittaker JL, Kalsoum R, Bilzon J, Conaghan PG, Crossley K, Dodge GR, Getgood A, et al. Journal article